FDA Clears First-in-Human Trial of a Dual-Targeted CAR-T Therapy for Colorectal Cancer

What This Article Covers

On September 10, 2026, the FDA cleared an investigational new drug (IND) application from the University of Colorado Anschutz Medical Campus to begin a first-in-human trial of an experimental CAR T-cell therapy engineered to attack two cancer-linked proteins at once, for adults with advanced colorectal cancer and pediatric patients with solid tumors that have stopped responding to standard treatment. This article covers what makes the therapy's "dual-targeting" design different from earlier CAR-T approaches, why solid tumors like colorectal cancer have been so resistant to this kind of cell therapy, and why an IND clearance — while a genuinely meaningful step — is still a long way from any evidence that the therapy actually works in patients.

A New Strategy Aimed at CAR-T's Toughest Problem

CAR-T therapy has transformed treatment for certain blood cancers, but it has struggled badly against solid tumors like colorectal cancer — a gap this site has covered before. Solid tumors are harder to treat with engineered T cells for several compounding reasons: they lack a single, uniform target the way leukemia and lymphoma cells often do, and they actively suppress the immune cells sent to attack them. The CU Anschutz team's approach, developed by researchers including Dr. Christopher Lieu, a professor of medical oncology, and Dr. Michael Verneris, a professor of pediatric oncology, tries to address both problems by engineering T cells to simultaneously recognize B7-H3, a protein expressed on most colorectal tumors, and target IL-8, a signaling molecule that promotes tumor growth, inflammation, and the immune-evasive environment that normally blunts a T cell's attack. "This is a very different way of thinking about how we treat cancer," Verneris said in the university's announcement, noting the goal was to find targets "present across many different cancers" rather than relying on a single marker that a tumor can more easily learn to hide. Lieu framed the broader appeal of the immunotherapy approach plainly: it offers "the opportunity to direct the immune system toward the cancer and potentially produce a much more durable response," in contrast to chemotherapy's less selective attack on both healthy and cancerous cells — a genuinely hopeful rationale for patients who have already exhausted standard options.

What the FDA Actually Cleared

It's worth being precise about what this news does and doesn't represent. The FDA's IND clearance is regulatory permission to begin testing the therapy in humans — it is not an approval, and it comes with no efficacy or safety data yet, because no patient has received the therapy. This will be a first-in-human, Phase 1 trial, the earliest and most cautious stage of clinical testing, designed primarily to establish a safe dose and watch for unexpected toxicity rather than to prove the treatment works. The therapy will be manufactured at the Gates Biomanufacturing Facility on the CU Anschutz campus, and the trial is expected to enroll adults with advanced colorectal cancer alongside pediatric patients with solid tumors who have already failed standard therapies — a population, as with most first-in-human cell therapy trials, that by definition has few remaining options. Enrollment is expected to begin around December 2026.

Why This Still Matters, Even Without Data Yet

None of the excitement here should be mistaken for evidence of benefit — there isn't any yet, and won't be for some time. But the underlying strategy is a genuine and active area of cancer immunotherapy research worth taking seriously: engineering cells to hit two targets rather than one is one of several approaches researchers are pursuing to try to close the gap between CAR-T's remarkable success in blood cancers and its far more limited track record against solid tumors, which make up the large majority of cancer cases and deaths. If a dual-target strategy like this one can help engineered T cells persist and function inside the hostile environment of a solid tumor, it could inform a broader class of future therapies well beyond colorectal cancer, which is exactly the kind of platform value that makes early trials like this one worth watching even before a single patient has been dosed.

Bottom Line

An FDA IND clearance for a first-in-human dual-targeted CAR-T trial is a real, meaningful step for a colorectal and pediatric solid-tumor patient population that badly needs new options, and the scientific rationale — attacking a tumor-associated protein and a tumor-promoting signal at the same time — is a thoughtful response to a well-documented weakness of earlier CAR-T designs. But this is still the very beginning: no patients have been treated, the trial hasn't started enrolling, and Phase 1 studies exist specifically because most experimental cancer therapies at this stage do not go on to show a clear benefit. Patients and families should treat this as a trial to watch, not a treatment to expect, and should look for actual safety and response data once the study is underway.